LONDON (Reuters) – Despite actions taken by corporations to arrange for Brexit, there may be nonetheless a threat of significant provide disruptions for 39 medicines because of Britain’s departure from the European Union, the bloc’s medicine regulator mentioned on Monday.
FILE PHOTO: The headquarters of the European Medicines Agency (EMA), is seen in London, Britain, April 25, 2017. REUTERS/Hannah McKay/File Photo
While that’s an enchancment on the scenario in July, when the European Medicines Agency warned about provide issues for 108 merchandise, the watchdog mentioned corporations answerable for the remaining medicine wanted to “step up their planning now”.
Of the excellent merchandise, 25 are human medicines and 14 are veterinary.
More than 2,600 medicine have some stage of manufacture in Britain and 45 million affected person packs are equipped from the United Kingdom to different European international locations every month, whereas one other 37 million movement in the other way, business figures present.
To make sure that EU drug advertising and marketing authorisations stay legitimate after Brexit, corporations are having to adapt their provide chains and authorized preparations to have sure operations primarily based in an EU member state.
Reporting by Ben Hirschler; Editing by Alexander Smith